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Abbreviations 
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ACC1         Acetyl-CoA carboxylase 1 
ACLY         ATP-citrate lyase 
ACSL         Long-chain acyl-CoA synthetase 
ATGL         Adipose triglyceride lipase 
BSA           Bovine serum albumin 
ChREBP       Carbohydrate responsive element-binding protein 
CHOP         CCAAT/enhancer binding protein homologous protein 
CPT1a         Carnitine palmitoyltransferase 1a 
DGAT         Acyl-CoA:diacylglycerol acyltransferase 
EDTA         Ethylenediaminetetraacetic acid 
Elovl6         Fatty acid elongase 6 
ER            Endoplasmic reticulum 
FABP1         Fatty acid binding protein 1 
FABPpm       Plasma membrane-associated fatty acid binding protein 
Fads           Fatty acid desaturase 
FAS           Fatty acid synthase 
FAT/CD36      Fatty acid translocase 
FATP          Fatty acid transport protein 
CGI-58        Comparative gene identification-58 
GPAT         Glycerol-3-phosphate acyltransferase 
GRP78        Glucose-regulated protein 78 kDa 
H&E          Hematoxylin and eosin 
HOMA-IR      Homeostatic model of insulin-resistance index 
LPK           L-type pyruvate kinase 
LCAD         Long-chain acyl-CoA dehydrogenase 
LXRα         Liver X receptor α 
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MCAD        Medium-chain acyl-CoA dehydrogenase 
ME1          Malic enzyme 1 
MS           Metabolic syndrome 
NAFLD       Nonalcoholic fatty liver disease 
ORO         Oil Red O 
PCE          Palmitoyl-CoA chain elongation 
PCR          Polymerase chain reaction 
PEPCK       Phosphoenolpyruvate carboxykinase 
PPARα        Peroxisome proliferator-activated receptor α  
SCD          Stearoyl-CoA desaturase 
SHR          Spontaneously hypertensive rats 
SHR/ND+     SHR/NDmcr-cp (+/+) rats 
SHR/NDcp     SHR/NDmcr-cp (cp/cp) rats 
SHRSP        Stroke-prone spontaneously hypertensive rats 
SREBP-1c     Sterol regulatory element binding protein-1c 
s-XBP1        Spliced X-box binding protein 1 
TLC          Thin-layer chromatography 
VLCAD       Very long-chain acyl-CoA dehydrogenase 
WKY         Wistar Kyoto rats 
 
 
 
 
 
 
Abstract     SHR/NDmcr-cp (cp/cp) rats (SHR/NDcp) are an animal model of metabolic 
syndrome. Our previous study revealed drastic increases in the mass of palmitic (16:0), oleic 
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(18:1n-9), palmitoleic (16:1n-7), cis-vaccenic (18:1n-7) and 5,8,11-eicosatrienoic acids in the 
liver of SHR/NDcp. However, detailed information on the class of lipid accumulated and the 
mechanism responsible for the overproduction of the accumulated lipid in the liver has not 
been obtained. This study aimed to characterize the class of lipid accumulated and to explore 
the mechanism underlying the lipid accumulation in the liver of SHR/NDcp, in comparison 
with SHR/NDmcr-cp (+/+) (lean hypertensive littermates of SHR/NDcp) and Wistar Kyoto 
rats. In the liver of SHR/NDcp, de novo synthesis of fatty acids (16:0, 18:1n-9 and 16:1n-7) 
and triacylglycerol (TAG) synthesis were up-regulated and fatty acid β-oxidation was 
down-regulated. These perturbations of lipid metabolism caused fat accumulation in 
hepatocytes and accumulation of TAG, which were enriched with 16:0, 18:1n-9 and 16:1n-7, 
in the liver of SHR/NDcp. On the other hand, no changes were found in hepatic contents of 
diacylglycerol and unesterified fatty acid (FFA); among FFAs, there were no differences in 
the hepatic concentrations of unesterified 16:0 and stearic acid between SHR/NDcp and two 
other groups of rats. Moreover, little change was brought about in the expression of genes 
responsive to endoplasmic reticulum stress in the liver of SHR/NDcp. These results may 
reinforce the pathophysiological role of stearoyl-CoA desaturase 1 and fatty acid elongase 6 
in the liver of SHR/NDcp. 
 
 Keywords     hepatic TAG accumulation · MUFAs · de novo lipogenesis · β-oxidation · 
SHR/NDmcr-cp (cp/cp) rat 
 
 
 
 
Introduction 
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Metabolic syndrome (MS) is a cluster of metabolic abnormalities, including visceral obesity, 
glucose intolerance, hypertension, and dyslipidemia with underlying insulin resistance. The 
coexistence of these disorders is considered to be increasingly linked to cardiovascular 
diseases. Several animal models of MS have been presented. One of these is SHR/NDmcr-cp 
(cp/cp) rats (SHR/NDcp). SHR/NDcp are an inbred subline of SHR/National Institute of 
Health (NIH)-corpulent rats [1]; namely, SHR/NIH-corpulent rats are bred by the Disease 
Model Cooperative Association (Dmcr), Japan, and the rats are named SHR/NDmcr-cp. 
Spontaneously hypertensive rats (SHR) were spontaneously developed as a colony from 
normotensive Wistar Kyoto rats (WKY) [2]. By crossing SHR with Sprague-Dawley rats, 
obese spontaneously hypertensive rats were obtained and named Koletsky rats, which were 
thought to be heterozygous for a recessive fatty (fa) gene [3]. The noncorpulent genes of this 
strain were eliminated by mating the rats with SHR, and the obtained rats were designated as 
SHR/NIH-corpulent rats [4]. SHR/NIH-corpulent rats are a congenic rat strain that has the 
genetic background of SHR and inherits obese characteristics from Koletsky rats, which have 
been demonstrated to carry a nonsense mutation in the leptin receptor gene [5]. Thus, 
SHR/NDcp as well as SHR/NIH-corpulent rats have corpulent “cp” gene(s), display visceral 
obesity, dyslipidemia and glucose intolerance in addition to hypertension and, therefore, 
constitute an animal model of MS [6, 7]. The gene currently established as the corpulent “cp” 
gene is the leptin receptor gene; however, the implications of other genes reflecting obesity 
and other symptoms of MS in this rat remain to be resolved. 
The liver is a major determinant of whole-body fatty acid and neutral lipid metabolism, 
and fatty liver is considered as the hepatic manifestation of MS [8]. Moreover, fatty acid 
species that exist in the liver are pathophysiologically critical [9–11]. Therefore, in a previous 
study, we compared the fatty acid profile of hepatic lipids among SHR/NDcp, WKY, SHR, 
stroke-prone spontaneously hypertensive rats (SHRSP) and SHR/NDmcr-cp (+/+) rats 
(SHR/ND+) (lean hypertensive littermates of SHR/NDcp), and demonstrated that SHR/NDcp 
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and the other four strains and/or substrains of rats were clearly disparate in terms of fatty acid 
profile [12]. This disparity was due to drastic increases in the mass of palmitic (16:0), oleic 
(18:1n-9), palmitoleic (16:1n-7), cis-vaccenic (18:1n-7) and 5,8,11-eicosatrienoic (20:3n-6) 
acids in the liver of SHR/NDcp. These findings are strongly suggestive of excessive lipid 
accumulation in the liver of SHR/NDcp. However, detailed characterization of the class of 
lipid accumulated in the liver of SHR/NDcp has not been performed; moreover, the 
mechanism underlying the overproduction of hepatic steatosis-related lipids is still unclear. 
This information is required to establish SHR/NDcp as a useful model of MS. In this context, 
the aims of this study were (1) to characterize the class of lipid accumulated in the liver and 
(2) to explore the mechanism underlying the lipid accumulation in the liver of SHR/NDcp, in 
comparison with SHR/ND+ and WKY. The present study showed that de novo synthesis of 
fatty acids (16:0, 18:1n-9 and 16:1n-7) and triacylglycerol (TAG) synthesis were up-regulated 
and fatty acid β-oxidation was down-regulated in the liver of SHR/NDcp; these perturbations 
of lipid metabolism caused fat accumulation in hepatocytes and accumulation of TAG, which 
were enriched with 16:0, 18:1n-9 and 16:1n-7. On the other hand, no changes were found in 
the hepatic contents of diacylglycerol (DAG) and unesterified fatty acid (FFA). Among FFAs, 
there were no differences in the hepatic concentrations of 16:0 and stearic acid (18:0) among 
SHR/NDcp, SHR/ND+ and WKY, and little change was brought about in expression of genes 
responsive to endoplasmic reticulum (ER) stress in the liver of SHR/NDcp. The 
pathophysiological significance of up-regulation of stearoyl-CoA desaturase (SCD) 1 and 
fatty acid elongase (Elovl) 6 in the liver of SHR/NDcp is discussed. 
 
Materials and Methods 
 
Materials 
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The following materials were obtained from the indicated commercial sources: [1-14C]16:0 
(56.0 Ci/mol) and [1-14C]18:1n-9 (55.0 Ci/mol) (American Radiolabeled Chemicals, Inc., St. 
Louis, MO); L-[U-14C]glycerol-3-phosphate (159 Ci/mol) and [2-14C]malonyl-CoA (56.0 
Ci/mol) (GE Healthcare, Little Chalfont, Buckinghamshire, UK); [1-14C]palmitoyl-CoA (60.0 
Ci/mol) (Moravek Biochemicals, Inc., Brea, CA); acetyl-CoA, malonyl-CoA, palmitoyl-CoA, 
stearoyl-CoA, glycerol-3-phosphate and bovine serum albumin (BSA) (essentially fatty acid 
free for enzyme assays and fraction V for protein assay) (Sigma Aldrich Japan, Tokyo, Japan); 
1,2-dioleoyl-sn-glycerol (Doosan Serdary Research Laboratories, Etobicoke, Ontario, 
Canada); rat insulin RIA kit (Millipore Corp., Billerica, MA); sterol regulatory element 
binding protein-1c (SREBP-1c) antibody (2A4) (Santa Cruz Biotechnologies Inc., Santa Cruz, 
CA); and anti-mouse IgG horseradish peroxidase-linked antibody (Cell Signaling, Danvers, 
MA). 
 
Animals       
 
All animal procedures were approved by Josai University’s Institutional Animal Care 
Committee in accordance with the Guidelines for Proper Conduct of Animal Experiments 
(Science Council of Japan). Fifteen-week-old male WKY, SHR/ND+ and SHR/NDcp were 
obtained from SLC (Hamamatsu, Japan). The animals were fed on a standard diet (CE-2; Clea 
Japan, Tokyo, Japan) ad libitum and allowed free access to water. The fatty acid composition 
(in mol %) of the standard diet was as follows: 16:0, 23.2 %; 16:1n-7, 2.0 %; 18:0, 2.4 %; 
18:1n-9, 19.7 %; 18:1n-7, 2.2 %; linoleic acid (18:2n-6), 42.1 %; α-linolenic acid (18:3n-3), 
3.6 %; arachidonic acid (20:4n-6), 0.2 %; 5,8,11,14,17-eicosapentaenoic acid (20:5n-3), 
2.9 %; 7,10,13,16,19-docosapentaenoic acid (22:5n-3), 0.3 %; and 
4,7,10,13,16,19-docosahexaenoic acid (22:6n-3), 1.3 %. After acclimatization, at the age of 22 
weeks, rats were anesthetized with diethyl ether, and blood was withdrawn from the inferior 
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vena cava. The liver was rapidly removed, washed with saline and weighed. Livers were used 
for histopathological analyses, analyses of lipids and glycogen, preparations of cytosol, 
microsomes and nuclear extracts, and preparation of liver slices. The portions of livers that 
were used for preparing cytosol and microsomes were perfused with ice-cold saline. To 
estimate the homeostatic model of insulin-resistance index (HOMA-IR), some rats were 
starved for 12 h and plasma was prepared from blood. 
 
Histopathological Analyses 
 
Isolated livers were fixed in 10% neutral-buffered formalin, embedded in paraffin wax, 
sectioned (3–4 μm thick) and stained with hematoxylin and eosin (H&E). To visualize fat 
deposition in the liver, frozen sections (10–12 μm thick) were cut in a cryostat and stained 
with Oil Red O (ORO) and with hematoxylin. The sections were evaluated by scanning the 
entire tissue specimen under low-power magnification (x40) and then confirmed under higher 
power magnification (x100, x200 and x400). All histopathological scoring and evaluation was 
carried out by blind evaluation without knowledge of the treatment. Images were obtained 
under a light microscope (Olympus BX51; Olympus, Tokyo, Japan) equipped with a DP50 
digital camera (Olympus). 
 
Lipid Analyses 
 
To determine the acyl composition of lipid classes, total lipid was extracted from portions 
of livers by the method of Bligh and Dyer [13], after the additions of known amounts of 
nonadecanoic acid, cholesteryl heptadecanoate and triheptadecanoin as internal standards. 
Cholesteryl ester (CE), TAG, FFA, DAG and phospholipid (PL) were separated by thin-layer 
chromatography (TLC) on silica gel G plates, which were developed with n-hexane/diethyl 
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ether/acetic acid (80:30:1, by vol.). The separated lipids were extracted from silica gel as 
described previously [14]; DAG and PL were extracted from silica gel after the addition of 
known amounts of methyl heptadecanoate as internal standards. The acyl composition of 
these lipids was determined as the methyl esters of fatty acids by gas chromatography 
(Shimadzu GC-2014; Shimadzu, Kyoto, Japan) [15]. To determine the acyl composition of the 
subclass of microsomal PL, total lipid was extracted from microsome suspensions [13]. 
Phosphatidylcholine (PtdCho), phosphatidylethanolamine (PtdEtn) and other lipids were 
separated by TLC on silica gel G plates, which were developed with 
chloroform/methanol/acetic acid/water (100:75:7:4, by vol.). The acyl composition of these 
PLs was determined as the methyl esters of fatty acids by gas chromatography. 
 
Biochemical Parameters 
 
Total lipid was extracted from portions of livers [13]. Cholesterol and lipid phosphorus was 
measured as reported previously [16, 17]. TAG, which was separated by TLC and extracted 
from silica gel, was determined using Triglyceride E-Test Wako (Wako Pure Chemicals, 
Osaka, Japan) [18]. Glycogen contents in the livers were measured by the enzymatic method 
as described previously [19]. Concentrations of glucose and insulin in plasma from fasted rats 
were determined by Glucose CII-test Wako (Wako Pure Chemicals) and rat insulin RIA kit, 
respectively, and HOMA-IR was calculated. 
 
mRNA Expression 
 
mRNA expression was analyzed by real-time quantitative PCR as described previously [12]. 
The sequences of primers used in this study are listed in Table 1. X-box binding protein 1 
(XBP1) mRNA splicing was analyzed as reported previously [20]; PCR products were 
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separated by electrophoresis in 2.5 % agarose gels and visualized by ethidium bromide 
staining. 
 
Enzyme Assays 
 
One portion of the perfused livers was homogenized with 1.5 volumes of a phosphate – 
bicarbonate buffer (70 mM KHCO3/85 mM K2HPO4/9 mM KH2PO4/1 mM dithiothreitol) (pH 
8.0) in a Potter glass-Teflon homogenizer. The homogenates were centrifuged at 20,000 x g 
for 10 min, and the supernatant was then centrifuged at 105,000 x g for 60 min. The resulting 
supernatant was used as cytosol. The other portion of the perfused livers was used for 
preparing microsomes as described previously [14]. All operations were carried out at 0–4 °C. 
Protein concentrations in the preparations were determined by the method of Lowry et al. [21] 
using BSA as a standard. The activity of fatty acid synthase (FAS) in cytosol was determined 
as the rate of NADPH oxidation [22]. The activities of SCD in microsomes were determined 
as described previously [14] and the activity is presented as the rate constant (k+) for 
stearoyl-CoA-stimulated re-oxidation of NADH-reduced cytochrome b5. Palmitoyl-CoA chain 
elongation (PCE) in microsomes was assayed using palmitoyl-CoA and [2-14C]malonyl-CoA, 
as described previously [23]. The activity of long-chain acyl-CoA synthetase (ACSL) in 
microsomes was assayed using [14C]16:0 [24]. Glycerol-3-phosphate acyltransferase (GPAT) 
activity in microsomes was determined using palmitoyl-CoA and [14C]glycerol-3-phosphate 
[25]. Acyl-CoA:diacylglycerol acyltransferase (DGAT) in microsomes was assayed using 
[1-14C]palmitoyl-CoA and dioleoylglycerol [26]. 
 
Nuclear Extracts and Western Blot Analyses 
 
Nuclear extracts of livers were prepared according to Sheng et al. [27]. Briefly, portions of the 
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livers were homogenized in 10 volumes of buffer A (10 mM Hepes (pH 7.6) containing 25 
mM KCl, 1 mM EDTA, 2 M sucrose, 10 % (v/v) glycerol, 0.15 mM spermine and 2 mM 
spermidine) supplemented with protease inhibitors (N-acetylleucylleucylnorleucinal at 50 
μg/mL, 0.1 mM Pefabloc, pepstatin A at 5 μg/mL, leupeptin at 10 μg/mL and aprotinin at 2 
μg/mL) using a Potter glass-Teflon homogenizer. The homogenate (10 mL) was layered over 
10 mL of buffer A in a RPS-27 rotor (Hitachi Koki, Tokyo, Japan) and centrifuged at 77,000 x 
g for 60 min at 4 °C. The resulting nuclear pellet was resuspended in 0.4 mL of 10 mM Hepes 
buffer (pH 7.6) containing 100 mM KCl, 2 mM MgCl2, 1 mM EDTA, 1 mM dithiothreitol and 
10% (v/v) glycerol supplemented with proteinase inhibitors, after which 0.04 mL of 4 M 
ammonium sulfate (pH 7.9) was added. Each mixture was centrifuged at 266,000 x g in a 
S120AT2 rotor (Hitachi Koki) for 45 min at 4 °C. The supernatant was used as nuclear extract. 
Protein concentrations in the nuclear extracts were measured by dye protein assay (BioRad, 
Hercules, CA).  
Samples containing 7.5–30 μg of protein were boiled in 0.063 M Tris–HCl (pH 6.8) 
containing 5 % (v/v) 2-mercaptoethanol, 2 % sodium dodecyl sulfate, 6 % (v/v) glycerol and 
0.002 % bromophenacylblue. The denatured samples were separated by sodium dodecyl 
sulfate/polyacrylamide gel electrophoresis on a 10 % gel and then transferred to a 
polyvinylidene difluoride membrane (BioRad) using a Trans-Blot Semi-Dry Electrophoretic 
Transfer Cell (BioRad). The membrane was blocked in Tris-buffered saline (pH 7.6) 
containing 0.1 % Tween-20, 5 % skim milk and 1 % BSA, and then incubated with mouse 
anti-SREBP-1c monoclonal antibody (1:500) overnight. The membrane was washed in 
Tris-buffered saline (pH 7.6) containing 0.1 % Tween-20, incubated with anti-mouse IgG 
horseradish peroxidase-linked antibody (1:2000) for 4 h, and washed three times in 
Tris–buffered saline (pH 7.6) containing 0.1 % Tween-20. Proteins were visualized using the 
ECLplus kit (GE Healthcare) and detected in a LAS-1000 (GE Healthcare). 
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Ex vivo Fatty Acid Esterification and Oxidation in Liver Slices 
 
The rats were killed and their livers were quickly removed. The left lobe was separated, and 
precision-cut liver slices (200 µm thick; 75–85 mg) were prepared with a Krumdieck tissue 
slicer (Alabama Research Development, Munford, AL) as described previously [28]. 
The rate of 18:1n-9 incorporation into lipids was determined essentially according to 
Iritani et al. [29] with some modifications. Liver slices were incubated in glass vials that 
contained 2 mL of Krebs–Henseleit buffer (pH 7.4), containing 5 mM glucose, 0.25 mM 
[1-14C]18:1n-9 (0.3 μCi) and 0.6 % BSA (essentially fatty acid-free) for 10 min at 37 oC under 
an O2–CO2 atmosphere (95:5, by vol.) with shaking (60 oscillations/min). At the end of the 
incubation, the liver slice was once transferred to a new vial that contained 2 mL of the 
above-mentioned incubation medium (except for [14C]18:1n-9), which was chilled at 0 oC. 
Then, immediately, the liver slice was transferred to a glass vial containing 
chloroform/methanol/water (1:2:0.8, by vol.), and lipids were extracted with Polytron 
(PT10-35) (Kinematica AG, Lazern, Switzerland) according to Bligh and Dyer [13]. CE, TAG, 
FFA, DAG and PL were separated by TLC. The separated lipids were extracted from silica gel 
as described above. The extract was mixed with scintillation fluid, and the radioactivity was 
then measured using a liquid scintillation counter (Aloka LSC 6100; Hitach-Aloka, Tokyo, 
Japan). 
The rate of 16:0 oxidation was determined as described previously [30]. Liver slices 
were incubated in glass vials that contained 2 mL of Krebs–Henseleit buffer (pH 7.4) 
containing 5 mM glucose, 0.25 mM [1-14C]16:0 (0.3 μCi) and 0.6 % BSA (essentially fatty 
acid-free) for 30 min at 37 oC under an O2–CO2 atmosphere (95:5, by vol.) with shaking (90 
oscillations/min). The vials were capped with rubber stoppers from which were suspended 
plastic center-wells. The incubation was terminated by the injection of 1 mL of 0.6 M HClO4 
into the vial, and 0.2 ml of 1 M benzethonium hydroxide in methanol was injected into the 
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center well. The vials were shaken (60 oscillation/min) for 45 min at room temperature to trap 
radio-labeled CO2 into benzethonium hydroxide. Then, the content of the center well was 
transferred to a counting vial and mixed with scintillation fluid, and the radioactivity was 
measured using a liquid scintillation counter. The liver slice was homogenized with the 
incubation mixture that was acidified with HClO4. After centrifugation at 1,500 x g for 10 min, 
the resulting supernatant was neutralized with 5 M KOH, and then its pH was adjusted to 4 
using 3 M acetate buffer (pH 4.0); the obtained aqueous phase was extracted five times with 5 
mL of petroleum ether to remove traces of the [14C]16:0. An aliquot of the aqueous phase was 
mixed with scintillation fluid, and the radioactivity was determined as acid soluble oxidation 
products. 
 
Statistical Analyses     
 
Homogeneity of variance was established using one-way analysis of variance. When a 
difference was significant (p < 0.05), Scheffé’s multiple range test was used as a post-hoc test. 
The results were considered to be significant if the value of p was < 0.05. 
 
Results 
 
Characteristics of SHR/NDcp 
 
Body weights of SHR/NDcp were 142% of those of WKY (Fig. 1a). Liver weights of 
SHR/NDcp were 2.1-fold of those of WKY and relative liver weights of SHR/NDcp were 
significantly higher than those of WKY and SHR/ND+ (Fig. 1b, c). Plasma insulin level and 
HOMA-IR of SHR/NDcp were strikingly higher than those of WKY and SHR/ND+ (Fig. 1h, 
i). Histopathological features of the H&E and ORO stained sections of livers from WKY, 
SHR/ND+ and SHR/NDcp are shown in Fig. 2a–f. In WKY, no vacuolation or lipid 
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deposition was observed in hepatocytes, whereas several sinusoidal cells such as stellate cells 
were ORO-positive (Fig. 2a, b). Minimal to mild fat accumulation was seen in SHR/ND+ (Fig. 
2c, d). In the case of SHR/NDcp, fat accumulation in hepatocytes was prominent. Diffuse 
macrovesicular fatty vacuolation and diffuse hepatocyte hypertrophy were seen (Fig. 2e, f). 
The intensity of fat accumulation in hepatocyte or hepatocyte hypertrophy of each animal was 
scored, as shown in Fig. 2g and h, respectively. There were no inflammatory changes such as 
hepatocellular necrosis, inflammatory cell infiltration and fibrosis in the liver of SHR/NDcp. 
TAG contents in the liver of SHR/NDcp were 8.6-fold higher than those of WKY, but there 
was no significant difference in hepatic contents of TAG between WKY and SHR/ND+ (Fig. 
1d). Notable differences were not observed in hepatic contents of either cholesterol or lipid 
phosphorus among the three groups of rats (Fig. 1e, f). There was no difference in the hepatic 
content of glycogen among WKY, SHR/ND+ and SHR/NDcp (Fig. 1g). Prominent 
enrichment of 16:0, 18:1n-9, 16:1n-7 and 18:1n-7 was observed in hepatic TAG in 
SHR/NDcp; 18:2n-6 and 18:3n-3 were also enriched in TAG, but to a lesser extent than 16:0 
and MUFAs (Table 2). On the other hand, no substantial enrichment of these fatty acids was 
found in PL, DG or CE in the liver of SHR/NDcp. 
 
Gene Expression 
 
To gain insight into the molecular basis of TAG accumulation in the liver of SHR/NDcp, the 
mRNA levels of key enzymes and proteins involved in the metabolism of fatty acid and TAG 
in the liver were measured (Table 3). In the liver of SHR/NDcp, the levels of mRNAs 
encoding enzymes involved in de novo fatty acid synthesis (FAS, acetyl-CoA carboxylase 1 
(ACC1), ATP-citrate lyase (ACLY) and malic enzyme 1 (ME1)),18:1n-9 synthesis (Elovl6 
and SCD1) and glycerolipid synthesis (GPAT1)) were up-regulated, but that of ACSL1 was 
unchanged. There were no significant differences in the levels of mRNAs for DGAT1, 
 14 
DGAT2 and GPAT4 among WKY, SHR/ND+ and SHR/NDcp. With regard to proteins 
participating in the translocation and trafficking of fatty acids, the levels of mRNAs for fatty 
acid translocase (FAT/CD36) and ACSL5 in SHR/NDcp were significantly higher than those 
in WKY and SHR/ND+, respectively, whereas there were no significant differences in the 
levels of mRNAs encoding fatty acid transport protein (FATP)2, FATP4, FATP5, plasma 
membrane-associated fatty acid binding protein (FABPpm), fatty acid binding protein1 
(FABP1) and ACSL1 between SHR/NDcp and SHR/ND+. The expression of the gene for 
ACSL3 was significantly down-regulated in SHR/NDcp. The level of mRNA for L-type 
pyruvate kinase (LPK) in SHR/NDcp was 2.4-fold higher than those in WKY and SHR/ND+, 
and no considerable difference was found in the level of mRNA for phosphoenolpyruvate 
carboxykinase (PEPCK) between WKY and SHR/NDcp. The levels of mRNAs encoding 
enzymes involved in fatty acid degradation (carnitine palmitoyltransferase 1a (CPT1a), 
medium-chain acyl-CoA dehydrogenase (MCAD), and adipose triglyceride lipase (ATGL)) 
were significantly down-regulated in the liver of SHR/NDcp. On the other hand, no 
differences were found in the levels of mRNAs for long-chain acyl-CoA dehydrogenase 
(LCAD), very long-chain acyl-CoA dehydrogenase (VLCAD) and comparative gene 
identification-58 (CGI-58) between SHR/NDcp and WKY or SHR/ND+. As for nuclear 
transcription factors, the levels of mRNA SREBP-1c were 1.7- and 1.8-fold higher than those 
in WKY and SHR/ND+, respectively. On the one hand, there was no considerable difference 
in the gene expression of carbohydrate responsive element-binding protein (ChREBP), 
peroxisome proliferator-activated receptor α (PPARα) or liver X receptor α (LXRα) between 
SHR/NDcp and SHR/ND+. 
 
De novo Fatty Acid Synthesis 
 
The activities of cytosolic FAS, microsomal SCD , microsomal PCE and microsomal ACSL in 
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the liver of SHR/NDcp were 7.7-, 5.0-, 4.0- and 1.3-fold, respectively, higher than those of 
WKY (Fig. 3a, b, c, d). The nuclear content of the mature 68-kDa form of SREBP-1c in the 
liver of SHR/NDcp was 6.4 and 9.1-fold higher than those of WKY and SHR/ND+, 
respectively (Fig. 4). 
 
TAG Synthesis 
 
Incorporations of [14C]18:1n-9 into TAG, DAG, CE and PL in the liver of WKY, SHR/ND+ 
and SHR/NDcp were compared ex vivo using liver slices (Fig. 5). The incorporation of 
radio-labeled 18:1n-9 into TAG in the liver slices of SHR/NDcp was 1.5 and 1.6-fold greater 
than those of WKY and SHR/ND+, respectively (Fig. 5a). There were no considerable 
differences in the incorporation of [14C]18:1n-9 into DAG, CE or PL among the three groups 
of rats (Fig. 5b, c, d). The concentration of unesterified 18:1n-9 in the liver of SHR/NDcp was 
1.9 and 1.7-fold higher than those of WKY and SHR/ND+, respectively (Table 4). It is, 
therefore, reasonable to assume that the absolute amount of 18:1n-9 incorporated into TAG in 
the liver slices of SHR/NDcp is much greater than that calculated on the basis of incorporated 
radioactivity. On the other hand, there was no significant difference in the activity of 
microsomal GPAT among WKY, SHR/ND+ and SHR/NDcp (Fig. 3e). Moreover, the activity 
of microsomal DGAT in the liver of SHR/NDcp was 73% of that of WKY, but no significant 
difference was observed in the activity between SHR/NDcp and SHR/ND+ (Fig. 3f). 
 
Fatty Acid Oxidation      
 
To confirm the functional significance of the reduced expression of the genes of ATGL, 
CPT1a and MCAD, rates of [14C]16:0 oxidation in the liver of WKY, SHR/ND+ and 
SHR/NDcp were compared ex vivo using liver slices (Fig. 6). The rates of formation of both 
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CO2 and acid soluble oxidation products in liver slices of SHR/NDcp were strikingly lower 
than those of WKY and SHR/ND+ (Fig. 6b, c). No significant difference was observed in the 
rate of [14C]16:0 oxidation between WKY and SHR/ND+ (Fig. 6a). It is worth noting that 
there was no significant difference in the concentrations of unesterified 16:0 in the livers 
among WKY, SHR/ND+ and SHR/NDcp (Table 4).  
 
PUFA Synthesis 
 
The content of 20:3n-6 in PL in the liver of SHR/NDcp was markedly higher than those of 
WKY and SHR/ND+; conversely, the content of 20:4n-6 in PL in the liver of SHR/NDcp was 
considerably lower than those of WKY and SHR/ND+ (Table 2). Levels of mRNA encoding 
Fads1 were 15 and 19 %, respectively, of those of WKY and SHR/ND+ (Table 3). On the 
other hand, there were no significant differences in mRNA levels of Fads2 and Elovl5 
between SHR/NDcp and SHR/ND+, whereas those of SHR/NDcp were significantly lower 
than those of WKY. 
 
ER Stress 
 
To explore whether perturbation of lipid metabolism in the liver causes ER stress in 
SHR/NDcp, the PtdCho/PtdEtn ratio in microsomal lipid and the expression patterns of 
several molecular indicators of ER stress were estimated (Fig. 7). The PtdCho/PtdEtn ratio in 
microsomal lipid in the liver of SHR/NDcp was 1.13 and 1.36-fold higher than those of WKY 
and SHR/ND+, respectively (Fig. 7a). Figure 7b shows the differences in the proportions 
(mol %) of fatty acids in microsomal PtdCho and PtdEtn between SHR/NDcp and WKY and 
between SHR/ND+ and WKY. In PtdCho of SHR/NDcp, the proportions of MUFAs and 
20:3n-6 were increased and, conversely, that of 20:4 was decreased. The extents of the 
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changes in PtdEtn of SHR/NDcp were not as great as those observed in PtdCho. No 
significant differences were observed in the expression of mRNAs encoding 
glucose-regulated protein 78 kDa (GRP78), CCAAT/enhancer binding protein homologous 
protein (CHOP) and XBP1 among WKY, SHR/ND+ and SHR/NDcp (Fig. 7c, d, e). Moreover, 
an increase in splicing of XBP1 mRNA was not observed in the liver of SHR/NDcp (Fig. 7f). 
 
Discussion 
 
The present study showed that deposition of TAG, but neither cholesterol nor PL, in 
hepatocytes was strikingly accelerated in SHR/NDcp in comparison with those in WKY and 
SHR/ND+. The current data revealed that the TAG content in the liver of SHR/NDcp was 
approximately 5 % by weight. Moreover, histopathological analyses demonstrated the 
presence of lipid droplets in hepatocytes of SHR/NDcp. However, inflammatory changes such 
as hepatocellular necrosis, inflammatory cell infiltration and fibrosis were not observed in the 
liver of SHR/NDcp. Therefore, the liver conditions in SHR/NDcp are largely considered to 
involve simple steatosis. Our previous study showed that a marked increase in the hepatic 
content of particular fatty acid species, 16:0, 16:1n-7, 18:1n-9, 18:1n-7 and 20:3n-6, is 
characteristic of SHR/NDcp in comparison with WKY, SHR, SHRSP and SHR/ND+ [12]. 
The present study confirmed that, in SHR/NDcp, the increased TAG was enriched with these 
fatty acid species, in particular 16:0 and 18:1n-9. 
Since fatty liver disease per se is linked to insulin resistance and thus by itself may be a 
major aggravating factor in the pathogenesis and progression of MS and its associated 
disorders [31], it is important to elucidate mechanism contributing to TAG accumulation in 
the liver of SHR/NDcp. Irrespective of the origin of FFAs, increased hepatic lipid supply most 
probably contributes to hepatic TAG accumulation [32]. Namely, hepatic lipid accumulation 
may result from an imbalance between lipid availability and lipid disposal; the excessive TAG 
 18 
deposition in the liver could be initiated by (1) increased de novo synthesis of fatty acid, (2) 
increased delivery of fatty acid from extra hepatic sources, (3) increased TAG synthesis, (4) 
decreased β-oxidation of fatty acid, and (5) decreased secretion of very low density 
lipoprotein, or several of these factors in combination. To deal with these possibilities, the 
approaches that we employed in the present study are as follows: first, to decide the targets on 
which the present study focuses, the expression of genes encoding enzymes and proteins for 
lipogenesis, fatty acid translocation/trafficking, fatty acid degradation, and nuclear 
transcription factors for the regulation of lipid metabolism was measured; second, the 
activities of enzymes and levels of proteins selected as targets in our study were determined; 
and third, TAG formation and fatty acid degradation were estimated ex vivo using 
precision-cut liver slices.  
As for de novo fatty acid synthesis, the activity of FAS in SHR/NDcp was strikingly 
higher than those in WKY and SHR/ND+, which is consistent with the higher expression of 
the mRNA for FAS in SHR/NDcp. The elevated expression of genes for ACC1, ACLY and 
ME1 in the liver of SHR/NDcp strongly suggests the stimulated supplies of both 
malonyl-CoA and NADPH for FAS. Moreover, the increased gene expression of LPK 
suggests that the supply of acetyl-CoA from glucose is also increased in hepatocytes of 
SHR/NDcp. These results, taken together, strongly imply the increased formation of 16:0 in 
the liver of SHR/NDcp, a suggestion that is consistent with the previous finding that the liver 
of SHR/NDcp contains 16:0 in large quantities [12]. Moreover, the 16:0 produced by FAS 
may be converted to palmitoyl-CoA by microsomal ACSL, the activity of which in the liver of 
SHR/NDcp was higher. Considering the ratios of 16:0/18:2n-6 and 18:1n-9/18:2n-6 (0.55 and 
0.47, respectively) in the chow diet on which rats were fed in the present study, the 
corresponding ratios of fatty acids in TAG in SHR/NDcp were markedly higher than those in 
WKY (16:0/18:2n-6 = 2.14 versus 0.88; 18:1n-9/18:2n-6 = 1.86 versus 0.63). These results 
suggest that the not small fraction of palmitoyl-CoA that was increasingly supplied was 
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elongated by PCE (encoded by Elovl6) and then desaturated by SCD (encoded by SCD1) to 
oleoyl-CoA and that palmitoyl-CoA and oleoyl-CoA produced by de novo fatty acid synthesis 
were utilized to form TAG. Similarly, the increased formations of palmitoleoyl-CoA and 
cis-vaccenoyl-CoA were likely to occur concurrently with the elevated formation of 
oleoyl-CoA. Activation of nuclear transcription factors, such as SREBP-1c, ChREBP and 
LXRα, is considered to contribute to the synthesis of 16:0 and 18:1n-9 through the 
up-regulation of FAS, SCD1 and Elovl6 [33, 34], and the increased de novo lipogenesis is 
secondary to the augmented expression of both SREBP-1c and ChREBP in insulin resistance 
and type 2 diabetes [35, 36]. The present study showed that the gene expression of SREBP-1c, 
but not ChREBP or LXRα, was significantly elevated in the liver of SHR/NDcp and that the 
nuclear content of the mature form of SREBP-1c in the liver of SHR/NDcp was markedly 
higher than those of WKY and SHR/ND+. These results are consistent with the findings that, 
in animal models, insulin has been shown to stimulate lipogenesis through SREBP-1c, even in 
insulin-resistant liver [37]. Shimomura et al. [38] have demonstrated that, despite the 
profound hepatic insulin resistance concerning glucose production through down-regulation 
of insulin-receptor-substrate-2, insulin continues to stimulate the production of SREBP-1c in 
the liver of insulin-resistant and hyperinsulinemic ob/ob mice. The present study showed that 
SHR/NDcp also exhibited evident insulin resistance and hyperinsulinemia, results that are in 
accordance with previously reported findings [6, 7]. These findings, taken together, prompt 
one to speculate that SREBP-1c transcription and protein expression are enhanced in the liver 
of SHR/NDcp by insulin action that is mediated through the 
insulin-receptor-substrate-1-dependent pathway. Moreover, the present results suggest that 
hyperinsulinemia plays a pivotal role in the up-regulation of lipogenic enzymes, FAS, ACC1, 
ACLY, ME1, SCD1 and Elovl6, in the liver of SHR/NDcp. 
The present study showed that formation of [14C]TAG from [14C]18:1n-9 in liver slices of 
SHR/NDcp was 1.5-fold higher than that of WKY, indicating that the rate of incorporation of 
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18:1n-9, which is delivered from the circulation, into TAG is up-regulated in the liver of 
SHR/NDcp in comparison with those in WKY and SHR/ND+. It should be noted here that it 
is impossible to calculate the absolute amounts of 18:1n-9 incorporated into TAG from these 
data, because [14C]18:1n-9 entered hepatocytes in the liver slices from the incubation medium 
and then mixed with endogenous unesterified 18:1n-9, which already exists in 18:1n-9 pools 
in hepatocytes, before being utilized for TAG synthesis. However, little information is 
available as to the number and size of 18:1n-9 pools in the liver. In the present study, therefore, 
the absolute amount of 18:1n-9 incorporated into TAG was not calculated, and the results are 
presented as the values of radioactivity in TAG. Since the hepatic concentration of 18:1n-9 in 
SHR/NDcp was 1.9-fold greater than that in WKY, the radiospecific activity of [14C]18:1n-9 
that entered hepatocytes in the liver slices may be reduced by endogenous unesterified 
18:1n-9 in SHR/NDcp to 1/1.9 of that of WKY. As a result, the absolute amount of TAG that 
was formed by incorporation of 18:1n-9 in the liver of SHR/NDcp is assumed to be roughly 
2.9-fold greater than that of WKY. However, the detailed role of hepatic pools of unesterified 
18:1n-9 remains controversial. There are two sources of fatty acids as substrates for TAG 
synthesis. One is the fatty acids taken up from the circulation, and the other is the fatty acids 
synthesized de novo in the liver. FAT/CD36 plays a central role in the uptake of circulating 
FFAs into hepatocytes [39]. The present study showed that the expression of the gene 
encoding FAT/CD36 in SHR/NDcp was 1.7- and 11-fold higher than those in WKY and 
SHR/ND+, respectively, and that the activity of microsomal ACSL was up-regulated in the 
liver of SHR/NDcp in association with the enhanced expression of the gene for ACSL5. 
Therefore, in the liver of SHR/NDcp, fatty acids as substrates for the synthesis of intrahepatic 
TAG may be increasingly supplied. It has been shown that increased FFA delivery to the liver 
stimulates the synthesis of TAGs in hepatocytes [32, 40]. Moreover, on the basis of the 
current results, it is most likely that the supplies of 16:0 and MUFAs, in particular 18:1n-9, 
that are synthesized de novo are augmented. Nevertheless, little evidence is available as to the 
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proportions of fatty acids in terms of their origin, namely, the circulation and/or de novo 
synthesis within hepatocytes, for TAG synthesis. It is known that 11 % of hepatic TAG is 
derived from de novo lipogenesis in rats that are healthy and are fed on a chow diet [41]. On 
the one hand, the contribution of de novo fatty acid synthesis to intrahepatic TAG may be 
greater in SHR/NDcp, because it has been reported that 26 % of TAG arises from de novo 
lipogenesis while serum FFAs account for up to 60 % of hepatic TAG in patients with 
nonalcoholic fatty liver disease (NAFLD) [42]. Collectively, even in the setting of hepatic 
over-accumulation of TAG, the contribution of de novo fatty acid synthesis in SHR/NDcp may 
be less than that of fatty acids derived from peripheral tissues or dietary fat. With respect to 
PUFA, the contents of 18:2n-6 and 18:3n-3 in hepatic TAG of SHR/NDcp were considerably 
higher than those of WKY and SHR/ND+, increases that are probably due to augmented 
uptake of these fatty acids from the circulation by the up-regulated FAT/CD36. 
As for the enzymes that contribute to TAG synthesis, the present study revealed that there 
was no up-regulation of activities of GPAT and DGAT in microsomes of the liver of 
SHR/NDcp, the results that were consistent with the expression of genes for GPAT4, DGAT1 
and DGAT2. Thus, there is an apparent discrepancy between the increased incorporation of 
[14C]18:1n-9 into TAG and the activities of the enzymes for TAG synthesis. However, similar 
findings were reported by Jamdar and Cao [43], who showed no differences in the 
microsomal activities of GPAT and DGAT between lean and obese Zucker rats, despite the 
hepatic content of TAG in obese Zucker rats being much greater than that in lean control. 
GPAT catalyzes the first, rate-limiting step in glycerolipid synthesis [44]. In the liver, GPAT 4 
resides in the ER, and GPAT1 is localized in the outer mitochondrial membrane [44]. 
Although GPAT1 is a mitochondrial isoform and DGAT resides in the ER, many studies 
support the important role for GPAT1 in regulating TAG synthesis in the liver [45]. The 
present study showed that the expression of the gene for GPAT1 in the liver of SHR/NDcp 
was higher than those in controls (WKY and SHR/ND+). This increased expression of GPAT1 
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mRNA in the liver of SHR/NDcp is reasonable because GPAT1 has been demonstrated to be 
regulated by insulin through SREBP-1c, but neither LXR nor ChREBP [46]. DGAT2 appears 
to play a dominant role in the liver [47]. The present study revealed that no difference was 
found in the gene expression of either DGAT1 or DGAT2 between SHR/NDcp and controls. 
However, 18:1n-9, which is increasingly taken up by FAT/CD36, may be converted to 
oleoyl-CoA by ACSL5 with elevated activity and the oleoyl-CoA is likely to be utilized as a 
substrate for DGAT in the ER. The strikingly elevated de novo formation of 18:1n-9 in the 
liver of SHR/NDcp may also supply a massive amount of substrate for DGAT2, because 
SCD1 has been shown to co-localize with DGAT2 in the ER [48] and is considered to impact 
the rate of glycerolipid synthesis [49, 50]. Collectively, the existing evidence suggests that the 
oversupply of substrates (16:0 and 18:1n-9), derived from the circulation and from de novo 
synthesis, for both GPAT and DGAT is a major cause of the increased formation of TAG in 
the liver of SHR/NDcp. 
It is considered that dysregulated mitochondrial metabolism of fatty acids is central in 
fatty liver [51]. The current data revealed that the rate of 16:0 β-oxidation in liver slices of 
SHR/NDcp was substantially lower than those of WKY and SHR/ND+, with the value being 
42 % of that of WKY. These results are consistent with the decreased expression of genes 
encoding CPT1a and MCAD. CPT1a is considered to catalyze the rate-limiting step in 
β-oxidation and to play a pivotal role in controlling TAG content in the liver [52]. ATGL is a 
key enzyme that is responsible for hydrolyzing the first fatty acid from TAG and deficiency of 
ATGL is known to cause progressive hepatic steatosis [53]. Thus, in addition to the increased 
de novo lipogenesis, the impairment of ATGL and mitochondrial β-oxidation is likely to 
increase automatically the availability of fatty acids for TAG synthesis, which seems to be 
causative of TAG accumulation in the liver of SHR/NDcp. 
The profiles of 20:3n-6, 20:4n-6, 20:5n-3 and 22:6n-3 are known to influence the levels 
of pro-inflammatory and anti-inflammatory products, such as different series of prostanoids, 
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different series of leukotrienes, lipoxins and resolvins. The present study revealed that the 
profile of PUFA in hepatic lipids, in particular PL, was considerably perturbed in SHR/NDcp. 
In hepatic PL in SHR/NDcp, 20:3n-6 was markedly enriched and the content of 20:4n-6 was 
significantly lower than that of controls. 20:4n-6 is known to be formed from 18:2n-6. 
Namely, 18:2n-6 is desaturated by Δ6 desaturase (encoded by Fads2) to 18:3n-6. This is 
followed by an elongation step mediated by fatty acid elongase (encoded by Elovl5) to 
20:3n-6, after which Δ5 desaturase (encoded by Fads1) forms 20:4n-6. The alterations in 
PUFA proportion that were brought about in the liver of SHR/NDcp may be elucidated by the 
facts that the expression of Fads1 was strikingly down-regulated and that, on the other hand, 
there were no significant differences in the expression of Fads2 and Elovl5 between 
SHR/NDcp and SHR/ND+. The expression pattern of Fads1, Fads2 and Elovl5 in the liver of 
SHR/NDcp is very similar to that of Zucker fa/fa rats [23]. These three genes are considered 
to share common regulatory characteristics including regulation by SREBP-1c and PPARα 
[33], regulation that is similar to those of SCD1 and Elovl6 [33]; the present results also 
demonstrated the increased nuclear content of the mature form of SREBP-1c and the marked 
up-regulation of SCD1 and Elovl6. However, the mechanism responsible for differential 
regulation of the expression of these three genes (Fads1, Fads2 and Elovl5) in the liver of 
SHR/NDcp remains to be demonstrated. The present results showed that, differently from 
20:4n-6, the contents of 20:5n-3 and 22:6n-3, the biosynthetic pathway of which also involves 
Δ5 desaturase, were little changed in the liver of SHR/NDcp. Although the mechanism behind 
the phenomenon that the formation of 20:4n-6 was reduced while biosynthesis of 20:5n-3 and 
22:6n-3 was not affected remains unresolved, it is noteworthy that the chow on which the rats 
were fed contained higher proportions of 20:5n-3 (2.9 %) and 22:6n-3 (1.3 %) than of 20:4n-6 
(0.2 %). Further study is required to understand whether an imbalance in PUFAs in the liver 
leads to induction or progression of metabolic-inflammatory pathologies in SHR/NDcp. 
Increased FFA and TAG contents in hepatocytes in insulin resistance have been 
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demonstrated to prompt ER stress [54]. Disturbance of fatty acid species composition, in 
particular overaccumulation of saturated fatty acids (SFAs), and phospholipid composition are 
starting to be considered as causes of hepatic ER stress [9, 10, 55]. Recently, it has been 
demonstrated that increased de novo fatty acid synthesis in the liver of ob/ob mice produces 
ample amounts of MUFA, which is effectively incorporated into PtdCho but not PtdEtn, 
which further distorts the PtdCho/PtdEtn ratio and impairs ER function [55]. Moreover, the 
increase in SREBP-1c expression and the resulting elevation of lipogenesis in the liver could 
be related to augmented ER stress in insulin resistance and type 2 diabetes [56, 57]. As for 
SHR/NDcp, the present study showed the increased de novo synthesis of 16:0 and 18:1n-9, 
the accumulation of TAG containing 16:0 and 18:1n-9 with high proportions, lipid droplets 
and a slightly but significantly higher PtdCho/PtdEtn ratio in ER in the liver. Moreover, 
SHR/NDcp exhibit insulin resistance and type 2 diabetes. These facts, taken together, might 
imply that SHR/NDcp are under hepatic ER stress. The present study confirmed, however, 
that there were no differences in the mRNA levels of GPR78, CHOP and s-XBP1 in the liver 
among WKY, SHR/ND+ and SHR/NDcp.  
The major findings of the present study are that SHR/NDcp exhibit (1) hepatic simple 
steatosis (fat accumulation as lipid droplets), (2) accumulation of TAGs containing 16:0, 
18:1n-9 and 16:1n-7 in high proportions, (3) up-regulation of de novo fatty acid synthesis 
(FAS, SCD1 and Elovl6), (4) up-regulation of TAG synthesis and (5) down-regulation of TAG 
degradation (ATGL, fatty acid β-oxidation). Numerous studies have suggested, using different 
kinds of experimental models, that SCD1 plays a central role in TAG accumulation. A typical 
example of this is a study using Zucker fa/fa rats, a model of MS; pharmacologic inhibition of 
SCD has been revealed to decrease the levels of TAGs in the liver and to improve glucose 
tolerance [58]. Thus, it seems possible that SCD1 is one of the major contributors to MS. On 
the other hand, compared with SCD1, little is known about Elovl6 in relation to MS. However, 
there is suggestive evidence indicating a close relationship between Elovl6 and SCD1 with 
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regard to disorder of lipid metabolism in the liver. The expression of the Elovl6 gene in 
liver-specific SCD1 knockout mice is not up-regulated in response to feeding on a 
high-carbohydrate diet, despite the fact that expression of the gene is inducible in normal liver 
[50]; conversely, in the liver of Elovl6 knockout mice, expression of the SCD1 gene is also 
down-regulated and the mice exhibit amelioration of insulin resistance [59]. More recently, 
we have revealed that SCD1 is markedly up-regulated, while the level of Elovl6 remains 
unchanged in the liver of Goto-Kakizaki rats, which exhibit type 2 diabetes without obesity, 
and that the content and proportion of 18:1n-9 in hepatic lipids of the rats are little changed 
[23]. These findings may imply that up-regulation of Elovl6 in conjunction with SCD1 is 
necessary for the increased formation of 18:1n-9. In contrast to other animal models [60], 
notable ER stress was not detected in the liver of SHR/NDcp. Previous studies on cultured 
cells have revealed that one can ward off the lipotoxic effects of SFAs by supplementation 
with MUFAs such as 18:1n-9, which promotes the incorporation of the SFAs into the TAG 
pool [11, 61, 62]. Namely, it is suggested that an increased saturated FFA/unsaturated FFA 
ratio in the liver triggers lipotoxicity and that this condition ensues when the hepatic capacity 
to remove saturated FFAs is overwhelmed. Saturated FFAs are not readily esterified by 
hepatocytes, conversion of SFAs to MUFAs, in particular 18:1n-9, being necessary for easier 
incorporation into TAG. Therefore, it is most likely that, owing to the marked up-regulation of 
SCD1 and Elovl6, hepatocytes of SHR/NDcp successfully evaded elevation of ER stress by 
partitioning excess SFAs independently of their origin (exogenous or de novo synthesized) 
into MUFAs that can be safely stored as TAG, an inert storage lipid. Thus, SCD1 in 
conjunction with Elovl6 may not only cause hepatic steatosis, but also make important 
contributions to prevent the progression of simple steatosis to severe steatosis or 
steatohepatitis as a molecular switch towards esterification of FFAs to TAGs in hepatocytes, 
which may protect the liver from lipotoxicity by buffering the accumulation of FFAs, in 
particular SFAs. The findings obtained in the present study may further support the 
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pathophysiological role of SCD 1 and Elovl6 in the liver of MS. 
Although there is growing evidence, not much is known with respect to fatty acid 
metabolism in the liver of humans in MS. NAFLD, namely TAG accumulation in the liver, is 
considered to be a feature of MS in humans [8]. Importantly, it has been confirmed, by human 
study, that the hepatic expression of SREBP-1c is markedly greater in the liver in NAFLD 
than in controls and that the expression of insulin-receptor-substrate-1 positively correlates 
with SREBP-1c [63]. It is known that hepatic lipogenesis, estimated in vivo, is increased in 
the liver of human subjects with obesity and hyperinsulinemia [64]. Hepatic SCD activity, 
which is estimated as 18:1n-9/18:0 or 16:1n-7/16:0 ratio in serum lipids, is also elevated in 
humans in MS [65, 66]. Hepatic Δ5 desaturase is down-regulated, whereas the role of Δ6 
desaturase in the liver of humans in MS or NAFLD remains controversial [65, 66, 67]. The 
fatty acid profile has been characterized as having higher proportions of 16:1n-7, 18:1n-9 and 
20:3n-6 in serum lipids [65, 67] and lower proportions of 18:2n-6 and 20:4n-6 in hepatic PL 
[68] in MS or NAFLD. To our knowledge, whether fatty acid elongases (Elovl6 and Elovl5) 
and fatty acid β-oxidation play central roles in the pathogenesis of MS or NAFLD in humans 
remains unclear. Thus, the current results regarding disorders of fatty acid metabolism in the 
liver of SHR/NDcp are very similar to those reported in the liver of human subjects in MS. 
Therefore, SHR/NDcp is most likely to be a useful model of human MS with hepatic simple 
steatosis. 
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Fig. 1     Characteristics of SHR/NDcp. (a), body weight; (b), liver weight; (c), relative 
liver weight; (d), TAG in the liver; (e), cholesterol in the liver; (f), lipid phosphorus in the 
liver; (g), glycogen in the liver; (h), insulin in plasma; (i), HOMA-IR. Values represent means 
± SD (n = 4–8). a, b, c Differences without a common superscript are statistically significant (p 
< 0.05). In the absence of a superscript, the differences in the means are not significant (p > 
0.05). 
 
Fig. 2     Representative images showing the histology of liver sections from WKY (a, b), 
SHR/ND+ (c, d) and SHR/NDcp (e, f) stained with H&E (a, c, e) and ORO (b, d, f), and the 
intensity of fat accumulation in hepatocytes (g) and hypertrophy (h). Sections (e) and (f ) 
show marked ORO-positive hepatocyte vacuolation. Scale bars indicate 200 μm and 500 μm 
in H&E- and ORO-stained sections, respectively. Insets show a higher magnification of the 
respective figure (b, d, f). The severity of histopathological findings was scored as (0) normal, 
(1) minimal, (2) mild, (3) moderate and (4) marked lipid deposition in hepatocytes. 
 
Fig. 3     Activities of enzymes involved in lipogenesis. (a), FAS in cytosol; (b), SCD in 
microsomes; (c), PCE in microsomes; (d), ACSL in microsomes; (e), GPTA in microsomes; 
(f), DGAT in microsomes. Values represent means ± SD (n = 4). a, b Differences without a 
common superscript are statistically significant (p < 0.05). In the absence of a superscript, the 
differences in the means are not significant (p > 0.05). 
 
Fig. 4     Protein expression of mature form of SREBP-1c in nuclear extracts from livers. 
Immunoblots were carried out on nuclear extracts from livers. Nuclear extracts of WKY (20 
μg of protein), SHR/ND+ (30 μg of protein) and SHR/ND+ (7.5 μg of protein) were loaded 
and separated by electrophoresis. Visible bands are SREBP-1c as indicated. Quantification for 
the amount of SREBP-1c was carried out using Multi gauge software (GE Healthcare) and 
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normalized by loaded protein content. Values represent ± mean SD (n = 3–4). a, b Differences 
without a common superscript are statistically significant (p < 0.05). 
 
Fig. 5    Incorporation ex vivo of [14C]18:1n-9 into lipids in liver slices. Liver slices were 
incubated with 0.25 mM [1-14C]18:1n-9 for 10 min at 37 oC. The lipids were extracted from 
liver slices and separated by TLC. (a), TAG; (b), DAG; (c), CE; (d), PL. Values represent 
means ± SD (n = 4). a, b Differences without a common superscript are statistically significant 
(p < 0.05). In the absence of a superscript, the differences in the means are not significant (p > 
0.05). 
 
Fig. 6    Oxidation ex vivo of [14C]16:0 in liver slices. Liver slices were incubated with 0.25 
mM [1-14C]16:0 for 30 min at 37 oC. The 14CO2 produced was trapped with benzethonium 
hydroxide, and acid-soluble oxidation products were extracted. (a), total β-oxidation products; 
(b), CO2; (c), acid soluble oxidation products. Values represent means ± SD (n = 4). a, b, c 
Differences without a common superscript are statistically significant (p < 0.05). 
 
Fig. 7    PL composition in microsomes and expressions of ER stress responsive genes in 
the liver. (a), relative abundance of PtdCho and PtdEtn in hepatic microsomes; (b), differences 
in proportion (mol %) of each fatty acid in PtdCho and PtdEtn of microsomes between the 
means of SHR/ND+ and WKY and between the means of SHR/NDcp and WKY. Microsomal 
lipids were extracted and microsomal PLs were separated by TLC, and fatty acids in 
individual PLs were determined by gas chromatography. Relative gene expressions of (c), 
GRP78; (d), CHOP; (e), XBP1 and (f), unspliced XBPl (uXBP1) and spliced XBP1(sXBP1). 
In (f), TU represents the results of the following experiments: McA-RH7777 cells were 
incubated for 3 h in Dulbecco’s modified Eagle’s medium supplemented with 10 μg/mL 
tunicamycin, and uXBP1 and sXBP1 were measured by real-time PCR followed by 
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electrophoresis. Values represent means ± SD (n = 4–8). a, b, c Differences without a common 
superscript are statistically significant (p < 0.05). In the absence of a superscript, the 
differences in the means are not significant (p > 0.05). 
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Table 1  Sequences of Primers Used for Real-Time PCR 
Primer (5' - 3') Accession No. 
Fatty acid synthase (FAS) F: CGCCGACCAGTATAAACCCA M76767 X14175 
R: GTTGTAATCGGCACCCAAGTC 
Acetyl-CoA carboxylase 1 (ACC1) F: AACGCCTTCACACCACCTTG J03808 
R: AGTCGCAGAAGCAGCCCAT 
ATP citrate lyase (ACLY) F: AAACTGTATCGCCCAGGCAGT J05210 
R: GTAACGCAGCACGTGATCCAT 
Malic enzyme 1 (ME1) F: ACAATACAGTTTGGCATTCCG NM_012600 
R: AGGATTCGCTCTCCATCAGTCA 
Stearoyl-CoA desaturase 1 (SCD1) F: TCACCTTGAGAGAAGAATTAGCA J02585 
R: TTCCCATTCCCTTCACTCTGA 
Fatty acid elongase 6 (Elovl6) F: AGAACACGTAGCGACTCCGAA AB071986 
R: CAAACGCGTAAGCCCAGAAT 
Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) F: CCGTGGTATCCTGAATTGGT NM_053437 
R: GGCGCTTCTCAATCTGAAAT 
Acyl-CoA:diacylglycerol acyltransferase 2 (DGAT2) F: ATCTTCTCTGTCACCTGGCT NM_001012345 
R: ACCTTTCTTGGGCGTGTTCC 
Glycerol-3-phosphate acyltransferase 1 (GPAT1) F: AGACACAGGCAGGGAATCCAC AF021348 
R: AATTCCCGGAGAAGCCCAG 
Glycerol-3-phosphate acyltransferase 4 (GPAT4) F: TTGGAGTCCTGGAATTTGCTGA NM_001047849 
R: GGCTAATCCCTGTGAATGCCA 
Fatty acid desaturase 1 (Fads1) F: TACAGGCAACCTGCAACGTTC NM_053445 
R: GGTGCCACCTTGTGGTAGTTGT 
Fatty acid desaturase 2 (Fads2) F: GCCACTTAAAGGGTGCCTCC BC081776 
R: TGCAGGCTCTTTATGTCGGG 
Fatty acid elongase 5 (Elovl5) F: ACCACCATGCCACTATGCTCA AB071985 
R: GGACGTGGATGAAGCTGTTG 
Fatty acid translocase (FAT/CD36) F: CGAAGGCTTGAATCCTACCG NM_031561 
R: TGTTGACCTGCAGTCGTTT 
Fatty acid transport protein 2 (FATP2) F: TTCAACAGTGGCGATCTCCTG NM_031736 
R: ACCGGAAGGTGTCTCCAACT 
Fatty acid transport protein 4 (FATP4) F: CCTGGTGTACTATGGATTCCGC NM_001100706 
R: GCTGAAAACTTCTTCCGGATCA 
(continued) 
Fatty acid transport protein 5 (FATP5) F: TTGCGAACGTACGGCAAGTAG NM_024143 
R: AAGGCGGTCTCGGAAGTAGAAG 
Plasma membrane-associated fatty acid binding protein (FABPpm) F: TCTGCCAATCCTATGCCAA NM_013177 
R: CACCCTTTTGGCTTCTTC 
Fatty acid binding protein 1 (FABP1) F: CGGCAAGTACCAAGTGCAGAG BC086947 
R: CTGACACCCCCTTGATGTCCT 
Long-chain acyl-CoA synthetase 1 (ACSL1) F: TCAGAGCAGTTCATCGGCATC NM_012820 
R: GTCGGTTCCAAGCGTGTCATA 
Long-chain acyl-CoA synthetase 3 (ACSL3) F: GGTGGCCAAAATGTGACAATG NM_057107 
R: AAACTCTCCAATATCGCCAGT 
Long-chain acyl-CoA synthetase 5 (ACSL5) F: CAAACATGGCTGCTTTCCTCA NM_053607 
R: ACCCTGGACAAGCCTCTCAAA 
Carnitine palmitoyltransferase 1a (CPT1a) F: AAGGCAGCGTTCTTCGTGA NM_031559 
R: GTCAAAGCATCTTCCATGC 
Medium-chain acyl-CoA dehydrogenase (MCAD) F: CTTTGCCTCTATTGCGAAGGC J02791 
R: TCCGAAAATCTGCACAGCATC 
Long-chain acyl-CoA dehydrogenase (LCAD) F: TGTATTGGTGCCATAGCCATGA L11276 
R: CCCAGACCTTTTGGCATTTGT 
Very long-chain acyl-CoA dehydrogenase (VLCAD) F: ACAGCTTTCGTAGTGGAACGGA D30647 
R: CTGGCACCTTGACTCCATCAA 
Adipose triglyceride lipase (ATGL) F: TCACCAACACCAGCATCCAA NM_001108509 
R: TCCATCTCGGTAGCCCTGTTT 
 Comparative gene identification-58 (CGI-58) F: TGCATAGATGGCAACTCTGGC NM_212524 
R: ATACACATAATGCCCTGCCCC 
 L-type pyruvate kinase (LPK) F: TGTGTACCACCGCCAGTTGTT M17685 
R: AGCACTTGAAGGAAGCCTCCA 
Phosphoenolpyruvate carboxykinase (PEPCK) F: TGCCTGGATGAAGTTTGATG NM_198780 
R: GCCCGGAGCAACTCCAAAAA 
Sterol regulatory element binding protein-1c (SREBP-1c) F: GGAGCCATGGATTGCACATT AF286469 
R: AGGAAGGCTTCCAGAGAGGA 
Carbohydrate responsive element-binding protein (ChREBP) F: AATAGAGGAGCTCAATGCT AB074517 
R: CCCAGAACTTCCAGTTGTGC 
(continued) 
Peroxisome proliferator-activated receptor α (PPARα) F: AATGCCCTCGAACTGGATGAC NM_013196 
R: CACAATCCCCTCCTGCAACTT 
Liver X receptor α (LXRα) F: CCACAGCTCAGCCCAGAA NM_031627 
R: GGCGTGACTCGAAGTCGGT 
 Glucose-regulated protein 78 kDa (GRP78) F: CCACCAGGATGCAGACATTG NM_013083 
R: AGGGCCTCCACTTCCATAGAG 
 CCAAT/enhancer binding protein homologous protein (CHOP) F: CTCTGCCTTTCGCCTTTGAG U36994 
R: ATAGGTGCCCCCAATTTCATC 
X-box binding protein 1 (XBP1) F: ACACGCTTGGGGATGAATG NM_001004210 
R: CCATGGGAAGATGTTCTGGG 
 β-Actin F: TGCAGAAGGAGATTACTGCC V01217 
R: CGCAGCTCAGTAACAGTCC 
Table 2  Fatty acid composition of hepatic lipids (μmol or nmol/g liver) 
WKY SHR/ND+ SHR/NDcp 
(μmol/g liver) 
TAG  
16:0 5.41 ± 0.75 a 4.85 ± 1.07 a 55.11 ± 22.46 b 
16:1n-7 0.50 ± 0.16 a 0.22 ± 0.08 a 15.56 ± 8.77 b 
18:0 0.65 ± 0.02 a 0.87 ± 0.06 a 1.85 ± 0.50 b 
18:1n-9 3.86 ± 0.41 a 3.09 ± 1.02 a 49.74 ± 24.36 b 
18:1n-7 0.85 ± 0.13 a 0.52 ± 0.18 a 7.43 ± 2.46 b 
18:2n-6 6.20 ± 1.06 a 4.75 ± 1.78 a 27.07 ± 14.74 b 
18:3n-3 0.23 ± 0.04 a 0.16 ± 0.05 a 1.13 ± 0.67 b 
20:3n-9 0.07 ± 0.01 a 0.07 ± 0.01 a 0.13 ± 0.03 b 
20:3n-6 0.09 ± 0.03 a 0.06 ± 0.03 a 1.11 ± 0.69 b 
20:4n-6 0.63 ± 0.17 ab 0.50 ± 0.23 a 1.47 ± 0.75 b 
20:5n-3 0.34 ± 0.06 0.12 ± 0.06 0.89 ± 0.65 
22:5n-3 0.60 ± 0.21 ab 0.24 ± 0.14 a 1.54 ± 1.00 b 
22:6n-3 0.89 ± 0.21 0.31 ± 0.16 2.02 ± 1.46 
Total 20.31 ± 3.06 a 15.74 ± 4.76 a 165.04 ± 77.95 b 
(μmol/g liver) 
DAG 
         16:0 1.14 ± 0.07 a 0.91 ± 0.05 a 1.68 ± 0.34 b 
16:1n-7 0.14 ± 0.02 a 0.08 ± 0.01 a 0.62 ± 0.14 b 
18:0 0.65 ± 0.11 0.51 ± 0.04 0.51 ± 0.08 
18:1n-9 0.53 ± 0.05 a 0.41 ± 0.01 a 1.33 ± 0.36 b 
18:1n-7 0.37 ± 0.03 ab 0.29 ± 0.01 a 0.46 ± 0.10 b 
18:2n-6 2.44 ± 0.24 a 2.07 ± 0.03 ab 1.92 ± 0.30 b 
18:3n-3 0.03 ± 0.00 a 0.02 ± 0.00 b 0.04 ± 0.01 a 
20:3n-9 0.03 ± 0.01 0.02 ± 0.01 0.03 ± 0.01 
20:3n-6 0.05 ± 0.00 a 0.03 ± 0.00 b 0.16 ± 0.02 c 
20:4n-6 0.59 ± 0.06 a 0.42 ± 0.06 b 0.35 ± 0.07 b 
20:5n-3 0.04 ± 0.00 a 0.02 ± 0.00 b 0.03 ± 0.00 c 
22:5n-3 0.05 ± 0.03 0.03 ± 0.00 0.03 ± 0.01 
22:6n-3 0.09 ± 0.01 a 0.05 ± 0.00 b 0.05 ± 0.01 b 
Total 6.16 ± 0.39 ab 4.86 ± 0.18 a 7.21 ± 1.28 b 
(nmol/g liver) 
CE 
16:0 356.4 ± 41.5 311.5 ± 22.0 384.8 ± 58.0 
16:1n-7 40.1  ± 15.0 a 30.2  ± 3.6 a 198.5  ± 83.5 b 
18:0 94.1 ± 18.4 98.0 ± 20.6 106.4 ± 25.9 
18:1n-9 152.4  ± 33.8 a 133.0  ± 20.0 a 347.9  ± 137.1 b 
18:1n-7 25.1  ± 4.7 a 15.4  ± 1.8 a 52.0  ± 19.5 b 
18:2n-6 144.0 ± 28.1 128.6 ± 18.0 174.4 ± 62.7 
18:3n-3 18.1 ± 8.6 18.6 ± 5.3 10.0 ± 9.0 
20:3n-9 29.1 ± 4.9 30.4 ± 3.6 32.2 ± 2.2 
20:3n-6 0.8  ± 0.2 a 1.1  ± 0.7 a 6.4  ± 2.7 b 
20:4n-6 78.1  ± 12.7 a 59.6  ± 16.1 a 129.3  ± 34.9 b 
20:5n-3 6.2  ± 1.7 a 3.4  ± 0.2 b 10.2  ± 1.1 c 
(continued) 
22:5n-3 2.8 ± 1.3 1.9 ± 1.6 3.6 ± 0.5 
22:6n-3 4.6  ± 1.2 ab 2.3  ± 1.9 a 6.9  ± 2.2 b 
Total 951.5  ± 153.9 a 834.0  ± 81.4 a 1462.6  ± 370.4 b 
(μmol/g liver) 
PL 
      16:0 13.00 ± 0.83 13.03 ± 0.77 11.45 ± 1.42 
16:1n-7 0.42 ± 0.11 a 0.25 ± 0.02 a 1.28 ± 0.19 b 
18:0 12.03 ± 0.53 a 12.03 ± 0.40 a 10.00 ± 0.34 b 
18:1n-9 2.15 ± 0.11 2.16 ± 0.17 2.39 ± 0.10 
18:1n-7 2.93 ± 0.21 a 2.03 ± 0.16 b 2.10 ± 0.47 b 
18:2n-6 9.33 ± 0.56 a 8.41 ± 0.49 a 6.56 ± 1.31 b 
18:3n-3 0.07 ± 0.01 0.09 ± 0.08 0.03 ± 0.01 
20:3n-9 0.02 ± 0.00 0.12 ± 0.20 0.05 ± 0.01 
20:3n-6 0.40 ± 0.03 a 0.31 ± 0.02 a 1.85 ± 0.33 b 
20:4n-6 15.03 ± 0.29 a 13.27 ± 0.74 b 9.61 ± 0.26 c 
20:5n-3 0.41 ± 0.12 a 0.11 ± 0.01 b 0.32 ± 0.10 a 
22:5n-3 0.75 ± 0.20 0.72 ± 0.02 0.51 ± 0.07 
22:6n-3 2.94 ± 0.32 a 3.74 ± 0.35 b 2.97 ± 0.33 a 
Total 59.48 ± 1.81 a 56.24 ± 2.93 a 49.11 ± 4.69 b 
Values represent means ± SD (n = 4). Differences in horizontal means without a common 
superscript (a, b, c) are significant (p < 0.05). In the absence of a superscript, the differences in the 
means are not significant (p > 0.05). 
Table 3  Gene expressions in the liver 
Genes WKY SHR/ND+ SHR/NDcp 
Lipogenesis 
FAS 1.0 ± 0.19a 0.58 ± 0.21a 3.03 ± 0.81b 
ACC1 1.0 ± 0.13a 0.79 ± 0.19a 2.93 ± 0.55b 
ACLY 1.0 ± 0.11a 0.60 ± 0.13a 2.07 ± 0.75b 
ME1 1.0 ± 0.40a 0.91 ± 0.36a 1.62 ± 0.32b 
SCD1 1.0 ± 0.34a 0.36 ± 0.28b 5.27 ± 0.62c 
Elovl6 1.0 ± 0.35a 1.07 ± 0.32a 47.53 ± 19.61b 
DGAT1 1.0 ± 0.11 0.83 ± 0.10 0.85 ± 0.13 
DGAT2 1.0 ± 0.21 0.82 ± 0.16 0.86 ± 0.08 
GPAT1 1.0 ± 0.16a 0.86 ± 0.18a 1.40 ± 0.31b 
GPAT4 1.0 ± 0.20 1.05 ± 0.14 0.94 ± 0.08 
PUFA biosynthesis 
Fads1 1.0 ± 0.15a 0.79 ± 0.19b 0.15 ± 0.09c 
Fads2 1.0 ± 0.19a 0.52 ± 0.25b 0.53 ± 0.26b 
Elovl5 1.0 ± 0.31a 0.71 ± 0.22ab 0.63 ± 0.15b 
Fatty acid trafficking 
FAT/CD36 1.0 ± 0.66a 0.15 ± 0.03b 1.66 ± 0.40c 
FATP2 1.0 ± 0.20a 0.87 ± 0.14ab 0.73 ± 0.11b 
FATP4 1.0 ± 0.34 1.16 ± 0.60 0.70 ± 0.18 
FATP5 1.0 ± 0.35a 0.75 ± 0.21ab 0.58 ± 0.17b 
FABPpm 1.0 ± 0.14a 0.91 ± 0.06ab 0.83 ± 0.12b 
FABP1 1.0 ± 0.24a 0.76 ± 0.14b 0.70 ± 0.12b 
ACSL1 1.0 ± 0.17 0.93 ± 0.11 0.97 ± 0.11 
ACSL3 1.0 ± 0.15a 1.37 ± 0.25b 0.44 ± 0.11c 
ACSL5 1.0 ± 0.11a 0.56 ± 0.17b 1.72 ± 0.03c 
Lipid degradation 
CPT1a 1.0 ± 0.38a 1.15 ± 0.13a 0.45 ± 0.06b 
MCAD 1.0 ± 0.19a 1.06 ± 0.17a 0.72 ± 0.04b 
LCAD 1.0 ± 0.13 1.04 ± 0.20 1.17 ± 0.15 
VLCAD 1.0 ± 0.18 0.95 ± 0.17 0.85 ± 0.08 
ATGL 1.0 ± 0.20a 1.09 ± 0.20a 0.61 ± 0.11b 
CGI-58 1.0 ± 0.41 0.59 ± 0.16 0.64 ± 0.11 
Glucose metabolism 
LPK 1.0 ± 0.25a 1.02 ± 0.33a 2.39 ± 0.46b 
PEPCK 1.0 ± 0.16ab 1.07 ± 0.14a 0.81 ± 0.14b 
Nuclear transcription factors 
SREBP-1c 1.0 ± 0.29a 0.93 ± 0.11a 1.71 ± 0.36b 
ChREBP 1.0 ± 0.43a 0.67 ± 0.25ab 0.45 ± 0.05b 
(continued) 
PPARα 1.0 ± 0.36 0.72 ± 0.21 0.73 ± 0.17 
LXRα 1.0 ± 0.26a 0.75 ± 0.10ab 0.67 ± 0.15b 
    Values represent means ± SD (n = 4–8). Differences in horizontal means without a common 
superscript (a, b, c) are significant (p < 0.05). In the absence of a superscript, the differences in 
the means are not significant (P > 0.05). 
Table 4  FFAs in the liver (nmol/g liver) 
WKY SHR/ND+ SHR/NDcp 
16:0 327.54 ± 51.30 350.34 ± 97.22 355.69 ± 50.47 
16:1n-7 5.52 ± 2.84 a 4.56 ± 1.00 a 20.35 ± 5.06 b 
18:0 68.98 ± 10.60 75.74 ± 13.41 74.42 ± 10.37 
18:1n-9 37.62 ± 8.17 a 41.31 ± 8.36 a 70.50 ± 8.66 b 
18:1n-7 15.90 ± 5.36 10.97 ± 3.57 16.37 ± 2.94 
18:2n-6 39.05 ± 12.65 40.70 ± 12.15 32.80 ± 6.80 
18:3n-3 12.27 ± 8.41 11.12 ± 2.01 19.32 ± 6.10 
20:3n-9 6.92 ± 7.79 2.80 ± 2.09 12.56 ± 4.00 
20:3n-6 0.43 ± 0.34 ab 0.32 ± 0.09 a 1.49 ± 0.89 b 
20:4n-6 21.25 ± 6.76 17.18 ± 5.51 16.00 ± 3.45 
20:5n-3 2.39 ± 0.97 ab 1.30 ± 0.39 a 4.22 ± 2.03 b 
22:5n-3 2.73 ± 1.94 2.88 ± 0.68 2.50 ± 1.08 
22:6n-3 5.55 ± 3.81 6.25 ± 3.53 5.98 ± 1.88 
Total 546.16 ± 83.61 565.47 ± 140.34 632.17 ± 84.35 
Values represent means ± SD (n = 4). Differences in horizontal means without a common 
superscript (a, b) are significant (p < 0.05). In the absence of a superscript, the differences in the 
means are not significant (p > 0.05). 
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